Payment overview · 2025
General Payments
$3,755.06
149 reported records · 25 companies
Healthcare provider profile · identity verified
Erick Gustavo Cruz, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · MAYAGUEZ, PR · NPI 1518121821
Verified facts
What the public records show
CMS Open Payments records show Erick Gustavo Cruz, M.D. received $3,755.06 in general payments during 2025 across 149 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 58 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eligard, Lenvima, Lupron Depot, Nerlynx, Ninlaro, Tagrisso, Verzenio.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPRON DEPOT as an associated drug or biological on 6475 records involving 3205 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Lupron Depot by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tagrisso by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
Eisai Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Lenvima as an associated drug or biological on 16833 records involving 7014 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lenvima by this doctor in 2024.
Eli Lilly Export S.A. Puerto Rico Branch reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERZENIO as an associated drug or biological on 301 records involving 104 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Verzenio by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LENVIMA as an associated drug or biological on 66 records involving 58 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lenvima by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROMACTA as an associated drug or biological on 47 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Promacta by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
PUMA BIOTECHNOLOGY, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NERLYNX as an associated drug or biological on 5139 records involving 3271 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nerlynx by this doctor in 2024.
TOLMAR, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIGARD as an associated drug or biological on 5834 records involving 3291 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Eligard by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NINLARO as an associated drug or biological on 3835 records involving 2551 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ninlaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $525.52 | 14.0% | 20 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $378.92 | 10.1% | 15 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $377.25 | 10.1% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $325.56 | 8.7% | 13 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $286.48 | 7.6% | 12 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $173.69 | 4.6% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $150.65 | 4.0% | 6 | 2025 |
| Eli Lilly Export S.A. Puerto Rico Branch | Unresolved — no canonical attribution shown | $140.95 | 3.8% | 5 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $134.26 | 3.6% | 5 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $126.26 | 3.4% | 5 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $124.42 | 3.3% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $122.34 | 3.3% | 5 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $114.99 | 3.1% | 5 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $98.99 | 2.6% | 4 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $89.38 | 2.4% | 4 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $82.36 | 2.2% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $78.20 | 2.1% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $77.26 | 2.1% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $74.40 | 2.0% | 3 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $50.20 | 1.3% | 2 | 2025 |
| Bayer Puerto Rico Inc. | Unresolved — no canonical attribution shown | $50.07 | 1.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $50.07 | 1.3% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $48.92 | 1.3% | 2 | 2025 |
| pharmaand GmbH | Unresolved — no canonical attribution shown | $48.92 | 1.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.00 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,755.06 | 149 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $286.48 | 12 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $279.39 | 11 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Pharmaceuticals, Inc | $177.39 | 7 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $140.95 | 5 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $140.95 | 5 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $134.26 | 5 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Pharmaceuticals, Inc | $127.17 | 5 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $126.26 | 5 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $126.26 | 5 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Pharmaceuticals, Inc | $124.88 | 5 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $124.45 | 5 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PBG PUERTO RICO LLC | $123.81 | 5 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PBG PUERTO RICO LLC | $123.81 | 5 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $114.99 | 5 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Drug | AstraZeneca Pharmaceuticals LP | $109.87 | 4 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $108.05 | 4 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $100.71 | 4 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $100.11 | 4 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $99.88 | 4 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $99.47 | 4 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $98.99 | 4 | 2025 |
Source payment records
|
|||||
| RUBRACA Normalized: rubraca |
Drug | TOLMAR, INC., pharmaand GmbH | $97.84 | 4 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $89.38 | 4 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $83.25 | 3 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $82.36 | 3 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $82.36 | 3 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $82.36 | 3 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $77.45 | 3 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $77.26 | 3 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $76.19 | 3 | 2025 |
Source payment records
|
|||||
| EMRELIS Normalized: emrelis |
Drug | ABBVIE INC. | $76.06 | 3 | 2025 |
Source payment records
|
|||||
| KYPROLIS Normalized: kyprolis |
Drug | Amgen Inc. | $75.07 | 3 | 2025 |
Source payment records
|
|||||
| LUPRON DEPOT Normalized: lupron depot |
Drug | ABBVIE INC. | $74.93 | 3 | 2025 |
Source payment records
|
|||||
| BREYANZI Normalized: breyanzi |
Biological | E.R. Squibb & Sons, L.L.C. | $74.53 | 3 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $74.40 | 3 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $53.20 | 2 | 2025 |
Source payment records
|
|||||
| Odomzo Normalized: odomzo |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $50.20 | 2 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $50.12 | 2 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $50.07 | 2 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Puerto Rico Inc. | $50.07 | 2 | 2025 |
Source payment records
|
|||||
| PEMAZYRE Normalized: pemazyre |
Drug | Incyte Corporation | $50.07 | 2 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $49.94 | 2 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $49.94 | 2 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PBG PUERTO RICO LLC | $49.88 | 2 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $48.93 | 2 | 2025 |
Source payment records
|
|||||
| IMDELLTRA (AMG757) Normalized: imdelltra amg757 |
Biological | Amgen Inc. | $47.27 | 2 | 2025 |
Source payment records
|
|||||
| LUMAKRAS Normalized: lumakras |
Drug | Amgen Inc. | $47.27 | 2 | 2025 |
Source payment records
|
|||||
| XGEVA Normalized: xgeva |
Biological | Amgen Inc. | $47.27 | 2 | 2025 |
Source payment records
|
|||||
| YONSA Normalized: yonsa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $27.31 | 1 | 2025 |
Source payment records
|
|||||
| Phesgo Normalized: phesgo |
Biological | Genentech USA, Inc. | $25.37 | 1 | 2025 |
Source payment records
|
|||||
| BLINCYTO Normalized: blincyto |
Biological | Amgen Inc. | $25.07 | 1 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Puerto Rico Inc. | $25.07 | 1 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PBG PUERTO RICO LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Puerto Rico Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIGARD Normalized: eligard |
Drug | TOLMAR, INC. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIGARD eligard |
2025 | Eligard | 2024 | 51 | exact normalized | Medicare Part D |
| Lenvima lenvima |
2025 | Lenvima | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LUPRON DEPOT lupron depot |
2025 | Lupron Depot | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NERLYNX nerlynx |
2025 | Nerlynx | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NINLARO ninlaro |
2025 | Ninlaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TAGRISSO tagrisso |
2025 | Tagrisso | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERZENIO verzenio |
2025 | Verzenio | 2024 | 108 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUPRON DEPOT open payments reported associated product |
CMS Open Payments — General Payments 6475 supporting records · 3205 recipient NPIs · example record 1201352804 |
Lupron Depot · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Eisai Inc. Exact reporting entity; no affiliate inference |
2025 | Lenvima open payments reported associated product |
CMS Open Payments — General Payments 16833 supporting records · 7014 recipient NPIs · example record 1244455619 |
Lenvima · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Eli Lilly Export S.A. Puerto Rico Branch Exact reporting entity; no affiliate inference |
2025 | VERZENIO open payments reported associated product |
CMS Open Payments — General Payments 301 supporting records · 104 recipient NPIs · example record 1186465135 |
Verzenio · 2024 Exact normalized brand match · 1 Part D row |
108 | 17 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | LENVIMA open payments reported associated product |
CMS Open Payments — General Payments 66 supporting records · 58 recipient NPIs · example record 1237995778 |
Lenvima · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PROMACTA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 47 recipient NPIs · example record 1200028032 |
Promacta · 2024 Exact normalized brand match · 1 Part D row |
82 | suppressed by CMS |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PUMA BIOTECHNOLOGY, INC. Exact reporting entity; no affiliate inference |
2025 | NERLYNX open payments reported associated product |
CMS Open Payments — General Payments 5139 supporting records · 3271 recipient NPIs · example record 1251741512 |
Nerlynx · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| TOLMAR, INC. Exact reporting entity; no affiliate inference |
2025 | ELIGARD open payments reported associated product |
CMS Open Payments — General Payments 5834 supporting records · 3291 recipient NPIs · example record 1237000419 |
Eligard · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | NINLARO open payments reported associated product |
CMS Open Payments — General Payments 3835 supporting records · 2551 recipient NPIs · example record 1223616278 |
Ninlaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 688 | 112 |
| Fulphila | Pegfilgrastim-Jmdb | 276 | 43 |
| Famotidine | Famotidine | 179 | 99 |
| Ondansetron Hcl | Ondansetron Hcl | 142 | 95 |
| Metoclopramide Hcl | Metoclopramide Hcl | 118 | 82 |
| Verzenio | Abemaciclib | 108 | 17 |
| Hydroxyurea | Hydroxyurea | 85 | 15 |
| Promacta | Eltrombopag Olamine | 82 | suppressed |
| Prednisone | Prednisone | 71 | 24 |
| Retacrit | Epoetin Alfa-Epbx | 68 | 51 |
| Eligard | Leuprolide Acetate | 51 | 11 |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 46 | suppressed |
| Famotidine | Famotidine/Pf | 46 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 46 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 46 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 41 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 41 | 15 |
| Tramadol Hcl | Tramadol Hcl | 41 | 22 |
| Lupron Depot | Leuprolide Acetate | 40 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 38 | suppressed |
| Letrozole | Letrozole | 37 | 11 |
| Ondansetron Odt | Ondansetron | 36 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | 18 |
| Sodium Chloride | 0.9 % Sodium Chloride | 32 | 18 |
| Omeprazole | Omeprazole | 28 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 27 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 15 |
| Bicalutamide | Bicalutamide | 24 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 24 | 12 |
| Revlimid | Lenalidomide | 24 | suppressed |
| Fentanyl | Fentanyl | 22 | 11 |
| Lenvima | Lenvatinib Mesylate | 22 | suppressed |
| Docetaxel | Docetaxel | 19 | suppressed |
| Meloxicam | Meloxicam | 18 | 13 |
| Nerlynx | Neratinib Maleate | 17 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Neulasta | Pegfilgrastim | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Fluorouracil | Fluorouracil | 14 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 14 | suppressed |
| Oxaliplatin | Oxaliplatin | 14 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Ninlaro | Ixazomib Citrate | 13 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | 11 |
| Tagrisso | Osimertinib Mesylate | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,755.06 · 149 records | AstraZeneca Pharmaceuticals LP | ADCETRIS, BLINCYTO, BOSULIF, BREYANZI, CALQUENCE, DARZALEX, ELAHERE, ELIGARD, ELREXFIO, EMRELIS, ENHERTU, EPKINLY, ERLEADA, Gavreto, IBRANCE, IMDELLTRA (AMG757), IMFINZI, Itovebi, JAKAFI, JAYPIRCA, KEYTRUDA, KISQALI, KYPROLIS, LIBTAYO, LUMAKRAS, LUPRON DEPOT, LUTATHERA, LYNPARZA, Lenvima, MI CANCER SEEK, MONJUVI, NERLYNX, NINLARO, Nubeqa, OJJAARA, OPDIVO, OPDUALAG, Odomzo, PEMAZYRE, PLUVICTO, Phesgo, Polivy, RUBRACA, RYBREVANT, Rezlidhia, SARCLISA, Stivarga, TAGRISSO, TAVALISSE, Trodelvy, VENCLEXTA, VERZENIO, Vitrakvi, Vonjo, WELIREG, XGEVA, YONSA, ZYNYZ | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eligard play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error